Melatonin not found to improve fatigue in patients with advanced cancer

the ONA take:

According to a new study published online ahead of print in the journal Cancer, researchers at Bispebjerg Hospital in Copenhagen, Denmark, have found use of oral melatonin at a dose of 20 mg was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.

For the study, researchers sought to assess the effect of melatonin on fatigue and other symptoms in patients with advanced cancer. Researchers enrolled 72 patients with stage IV cancer who reported significant fatigue and randomly assigned them to receive 1 week of melatonin 20 mg or placebo orally each night. Patients then crossed over and received the opposite treatment for 1 week.

Of those, 50 patients completed the study and 44 were 100% compliant with the interventions. Results showed no difference in physical fatigue or other quality of life measures between melatonin and placebo.

Panel recommends at least 7 hours of sleep a night for most adults
Oral melatonin was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.
Patients with advanced cancer often experience fatigue and other symptoms that negatively impact their quality of life. The current trial investigated the effect of melatonin on fatigue and other symptoms in patients with advanced cancer.
READ FULL ARTICLE From Wiley Online Library
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs